A new drug developed by a Colorado biotech company has cleared regulatory hurdles in the US and will likely be the first in the world to treat a common cold, according to the US Food and Drug Administration.
Westland Pharmaceuticals announced Wednesday that it will apply for a patent on the drug, called K-100.
K-100 has been used for about two decades to treat patients with common colds including SARS-CoV-2.
The drug’s inventor, Peter Rocha, said he hoped to develop a vaccine for SARS in the next five years.
He said the drug was approved by the FDA in 2014, but was delayed after concerns about the drug’s safety and efficacy.
The FDA said it approved the drug because it meets the criteria for a new and improved drug.
The agency said in a statement the FDA “is pleased to announce the application for a Phase 2/3 clinical trial of the K-101 vaccine in the United States for Sars-Cov-2, as well as approval of K-104 for the SARS vaccine in Australia.”
K-101 was approved in 2016 for treating common cold-related symptoms in children, and was approved for use in adults in 2017.
It has been shown to reduce the duration of symptoms and prevent the development of complications, including pneumonia.
The drug has not been shown in humans to have any benefit in people with SARS.
It was also approved for another common cold vaccine, the Sirolimus vaccine, in 2018.
A second study published in the journal Vaccine is expected to show similar results in humans.
Rocha said K-103 would also be available in the U.S. in a year.
He declined to disclose the price.
The company expects to have the drug on the market by 2020, according the company.
It’s unclear if K-102 will be available.